Notwithstanding the recent pessimism, U is still rated with a best-in-class "A" growth grade. In other words, bullish U investors could point out that the market could have been overly bearish on ...

Smack in the middle of the American Society of Hematology (ASH) annual meeting in San Diego, presenter Spark Therapeutics Inc. disclosed a licensing deal that harnesses the synthetic vaccine particles ...